Las Vegas, NV–CV Sciences announced in a press release that its PlusCBD Oil products were used in a study examining the clinical benefit of cannabidiol (CBD) for the treatment of Post-Traumatic Stress Disorder (PTSD).
The 8-week study, titled “Cannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case Series” and published in The Journal of Alternative and Complementary Medicine, is the first study to date examining the clinical benefit of CBD for patients with PTSD, according to the researchers.
The researchers examined the effect of oral CBD on symptoms of PTSD in 11 adult patients at an outpatient psychiatry clinic. In addition to CBD, patients received routine psychiatric care, including concurrent treatment with psychiatric medications and psychotherapy.
The finding: 91% of study subjects experienced a decrease in PTSD symptom severity. The researchers note that CBD also appeared to offer relief in a subset of patients who reported frequent nightmares. What’s more, they add, CBD was generally well tolerated, and no patients discontinued treatment due to side effects.
“We were impressed with the improvements seen in the subjects,” study author Scott Shannon, M.D., Department of Psychiatry, University of Colorado Denver, said in the CV Sciences press release. “These findings can help inform future clinical investigations, including double blind, placebo-controlled trials, to confirm the response to CBD that was observed in this study.”
Joseph Dowling, CEO of CV Sciences, added, “CV Sciences’ continued commitment to furthering scientific research allows us to better understand the benefits of CBD or a wide range of indications. After more than 80 years of prohibition, hemp CBD research has been severely hindered, but with the passage of the 2018 Farm Bill, we are beginning to understand the clinical benefits of CBD through scientific rigor. While we recognize that dietary supplements can’t be marketed for treating disease, we are pleased to support scientific progress by providing our PlusCBD Oil products to researchers and look forward to continued research on the clinical benefits of CBD for patients with PTSD and other indications.”